Position of the Transparency Council – Qinlock (ripretinib)
At its meeting on 24 February 2025, the Transparency Council adopted position No. 20/2025 on the evaluation of the medicinal product Qinlock (ripretinib) in the framework of the medicinal product program “Treatment of patients with advanced gastrointestinal stromal tumor (GIST) (ICD-10: C.15, C.16, C.17, C.18, C.20, C.48)”